1219 Nonclinical safety evaluation of sacituzumab govitecan, a TROP-2-directed antibody drug conjugate (ADC), for non-muscle invasive bladder cancer

McMahon, Carrie; Diehl, Lauri; Tatalick, Laurie; Boggs, Jennifer M.; Mohanan, Sunish; Mah, In Kyoung; Kardos, Jordan; Chou, Chih-Chien; Niu, Congrong; Dave, Rutwij A.; Scholler, Nathalie; Lai, Yurong

doi:10.1136/jitc-2022-sitc2022.1219

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is further complicated by the poor penetration abilities of the drugs used in instillation chemotherapy. Encouragingly, current animal experiment data indicate that the toxicity of the payloads does not cause more significant damage, and the overall effect of ADCs instillation is good (63,64). Therefore, for urothelial carcinoma, considering the good targeting of ADCs, it is worthwhile to reduce costs, even at the expense of some efficacy, to achieve more widespread and universal application, thereby achieving collective benefits.…”

Section: Challenges and Future Directions For Adcs In Urothelial Cancermentioning

confidence: 99%

Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives

Li,

Xie,

Deng

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Urinary tumors primarily consist of kidney, urothelial, and prostate malignancies, which pose significant treatment challenges, particularly in advanced stages. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach, combining monoclonal antibody specificity with cytotoxic chemotherapeutic payloads. This review highlights recent advancements, opportunities, and challenges in ADC application for urinary tumors. We discuss the FDA-approved ADCs and other novel ADCs under investigation, emphasizing their potential to improve patient outcomes. Furthermore, we explore strategies to address challenges, such as toxicity management, predictive biomarker identification, and resistance mechanisms. Additionally, we examine the integration of ADCs with other treatment modalities, including immune checkpoint inhibitors, targeted therapies, and radiation therapy. By addressing these challenges and exploring innovative approaches, the development of ADCs may significantly enhance therapeutic options and outcomes for patients with advanced urinary tumor.

show abstract

Section: Challenges and Future Directions For Adcs In Urothelial Cancermentioning

confidence: 99%

Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives

Li,

Xie,

Deng

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

1219 Nonclinical safety evaluation of sacituzumab govitecan, a TROP-2-directed antibody drug conjugate (ADC), for non-muscle invasive bladder cancer

Cited by 1 publication

References 0 publications

Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives

Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives

Contact Info

Product

Resources

About